Get the Stockscreener App
77.56
0.10%
-0.08
Corcept Therapeutics Inc stock is traded at $77.56, with a volume of 1.20M.
It is down -0.10% in the last 24 hours and up +5.91% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$77.64
Open:
$77.64
24h Volume:
1.20M
Relative Volume:
0.76
Market Cap:
$8.23B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
61.56
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-1.44%
1M Performance:
+5.91%
6M Performance:
+34.47%
1Y Performance:
+148.51%
1-Day Range:
$75.12
$78.70
1-Week Range:
$75.12
$80.64
52-Week Range:
$28.04
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
77.56 | 8.34B | 628.56M | 141.82M | 142.60M | 1.26 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World
Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World
Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent
Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders
Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance
Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World
Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance
Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com
Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance
Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now - Insider Monkey
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call - ACCESS Newswire
Insider Sell: William Guyer Sells Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
HC Wainwright Has Pessimistic Outlook of CORT Q2 Earnings - Defense World
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $143.25 - Defense World
Corcept Therapeutics chief development officer sells $524,652 in stock By Investing.com - Investing.com India
Corcept Therapeutics chief development officer sells $524,652 in stock - Investing.com Australia
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
Corcept Therapeutics (NASDAQ:CORT) Raised to Buy at StockNews.com - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2025 Earnings Call Transcript - Insider Monkey
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall - MSN
Corcept Therapeutics price target lowered to $135 from $150 at Truist - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Down on Insider Selling - Defense World
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS - Yahoo Finance
Corcept Therapeutics (CORT) Faces Price Target Cut Amid Revenue Concerns | CORT Stock News - GuruFocus
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts - Benzinga
Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating - marketscreener.com
H.C. Wainwright cuts Corcept Therapeutics target to $145 By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Receives Revised Price Target from A - GuruFocus
Corcept Therapeutics (CORT) Receives Revised Price Target from Analyst | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Pr - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Price Target | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Es - GuruFocus
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS A - GuruFocus
Corcept Therapeutics (CORT) Pre-Earnings Options Activity Sugges - GuruFocus
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars By Stocktwits - Investing.com India
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges - GuruFocus
Decoding Corcept Therapeutics Inc (CORT): A Strategic SWOT Insig - GuruFocus
Corcept Therapeutics Reports Q1 2025 Financial Results - TipRanks
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars - MSN
Corcept: Q1 Earnings Snapshot - MySA
Corcept Therapeutics (CORT) Anticipates Future Growth Amid Reven - GuruFocus
Corcept Therapeutics (CORT) Set to Announce Q1 Earnings - GuruFocus
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
May 16 '25 |
Option Exercise |
21.65 |
32,262 |
698,472 |
37,749 |
| Guyer William | Chief Development Officer |
May 16 '25 |
Sale |
74.17 |
32,262 |
2,393,014 |
5,487 |
| MAHONEY DAVID L | Director |
May 16 '25 |
Option Exercise |
6.55 |
30,000 |
196,500 |
30,000 |
| MAHONEY DAVID L | Director |
May 16 '25 |
Sale |
74.23 |
27,352 |
2,030,452 |
0 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):